Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions.

@article{Vermes2000FlucytosineAR,
  title={Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions.},
  author={Andr{\'a}s Vermes and H. J. Guchelaar and Jacob B. Dankert},
  journal={The Journal of antimicrobial chemotherapy},
  year={2000},
  volume={46 2},
  pages={
          171-9
        }
}
Flucytosine (5-FC) is a synthetic antimycotic compound, first synthesized in 1957. It has no intrinsic antifungal capacity, but after it has been taken up by susceptible fungal cells, it is converted into 5-fluorouracil (5-FU), which is further converted to metabolites that inhibit fungal RNA and DNA synthesis. Monotherapy with 5-FC is limited because of the frequent development of resistance. In combination with amphotericin B, 5-FC can be used to treat severe systemic mycoses, such as… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 211 CITATIONS, ESTIMATED 64% COVERAGE

Cryptococcus gattii infection in solid organ transplant recipients: description of Oregon outbreak cases.

  • Transplant infectious disease : an official journal of the Transplantation Society
  • 2015
VIEW 8 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Mécanismes moléculaires de la résistance aux antifongiques chez candida glabrata

VIEW 9 EXCERPTS
CITES METHODS, BACKGROUND & RESULTS
HIGHLY INFLUENCED

Invasive fungal infections: a review of epidemiology and management options.

  • Journal of medical microbiology
  • 2006
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2001
2019

CITATION STATISTICS

  • 23 Highly Influenced Citations

  • Averaged 14 Citations per year from 2017 through 2019

Similar Papers

Loading similar papers…